ClinicalTrials.gg
RecruitingNCT05822609RT1DUpdated Jun 2, 2026

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

A Phase 2 interventional study of Semaglutide and Placebo in Diabetic Kidney Disease and Type 1 Diabetes, sponsored by University of Washington. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by University of Washington · Phase 2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.

Planned enrollment
65th of 120
60 · median 79
Started
2024
with 5 others
Phase 2
54 of 153
5 open now
Primary completion
2027-06
later than 17 of 30 live
Registered
135th of 153
by date
Lead sponsor
4 of 153
University of Washington

Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 65th largest by planned enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2024, is one of 54 in phase 2, reaches primary completion later than 17 of the 30 other live ones, and was the 135th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Diabetic Nephropathies with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes. The secondary objective is to determine the effects of semaglutide on change in kidney parameters (including kidney oxygenation and function) measured by MRI from baseline to 26 weeks in type 1 diabetes. Other objectives are to determine the glycemic effects and safety of semaglutide in type 1 diabetes.

Read the detailed description

A parallel-group, double-blind, placebo-controlled, randomized study will rigorously test effects of semaglutide on the kidney. Real-time continuous glucose monitoring will be used to control glycemia during study run-in (prior to randomization) and during active therapy, which investigators anticipate will lead to similar glycemic control according to treatment assignment and ability to assess effects independent of glycemia. The trial duration is 26 weeks, a period of time sufficient to gradually titrate study medications to maximum target dose (over 12 weeks) and then observe the full short-term effect of semaglutide on the kidney.

Study Aims and Hypotheses:

Aim 1: Determine the effects of semaglutide vs. placebo on kidney oxygenation in type 1 diabetes. Hypothesis 1: Semaglutide will improve kidney oxygen availability in adults with type 1 diabetes.

Aim 2: Determine the effects of semaglutide vs. placebo on urine albumin-creatinine ratio and estimated glomerular filtration rate in type 1 diabetes. Hypothesis 2: Semaglutide will lower albuminuria and slow estimated glomerular filtration rate decline in adults with type 1 diabetes.

Aim 3: Determine the glycemic effects and safety of semaglutide vs. placebo in type 1 diabetes. Hypothesis 3: Semaglutide will reduce total daily insulin dose and improve glycemic variability without increasing risk of severe hypoglycemia or diabetic ketoacidosis in adults with type 1 diabetes.

03

Conditions studied

  • Diabetic Kidney Disease
  • Type 1 Diabetes

Keywords

  • Glucagon-like peptide-1 receptor agonist
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) with type 1 diabetes
  • Diabetes duration of ≥5 years
  • Persistent urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g, on the most recent two measurements within the prior 3 years
  • Estimated ≥ 20 mL/min/1.73m2
  • Stable doses of drugs altering blood pressure (e.g., Angiotensin-converting enzyme inhibitor) required for at least 4 weeks prior to randomization, and requested for the duration of the trial
  • Stable doses of lipid-lowering medications required for at least 4 weeks prior to randomization, and requested for the duration of the trial
  • Adequate method for females of

Exclusion criteria

Exclusion Criteria:

  • >9%, recent diabetic ketoacidosis, hyperosmolar hyperglycemic state or severe illness requiring hospitalization in past 30 days
  • Other causes of diabetes mellitus, including type 2 diabetes and maturity-onset diabetes of the young (MODY)
  • Chronic kidney disease unrelated to diabetes
  • Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or thyroid nodule palpated by endocrinologist at screening
  • Personal history of pancreatitis
  • Current/planned pregnancy or nursing
  • Uncontrolled thyroid disease or hypertension (Systolic blood pressure [SBP] ≥ 160 mm Hg or diastolic blood pressure [DBP] ≥ 100 mm Hg despite treatment)
  • Proliferative retinopathy with treatment in the past 6 months
  • Uncontrolled or potentially unstable diabetic retinopathy or maculopathy, verified by fundus examination with pupil dilation unless performed using a digital fundus photography camera specified for non-dilated examination
  • More than 2 severe hypoglycemic episodes (requiring glucagon and/or assistance from another person) in the past 6 months
  • Frequent hypoglycemia during the last two weeks of the study run-in phase (time below range [\<70 mg/dL] ≥4%)
  • Pramlintide and the use of glycemia treatments not approved for type 1 diabetes by the FDA, e.g., metformin, SGT-2 inhibitor, GLP-1 receptor agonist, closed loop insulin delivery using unapproved algorithms
  • Significant systemic conditions or treatment such as cancer or immunomodulators
  • Known liver disease other than non-alcoholic fatty liver disease (NAFLD) or (AST) or alanine aminotransferase (ALT) >100 IU/L, history of severe gastrointestinal disease (e.g., gastroparesis) or gallstones
  • \<20 kg/m2
  • Known or suspected allergy/sensitivity to semaglutide or its
  • Pregnant, breast feeding, or the intention of becoming pregnant
  • The receipt of any drug within 3 months prior to this trial
  • Previously randomized in this trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Semaglutide

    Semaglutide group from 0.25mg to 1.0mg

    Drug: Semaglutide

  • Placebo comparator
    Placebo

    Placebo group

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in urine albumin excretion

    Measured as mean of multiple urine albumin-creatinine ratio measurements in spot urine

    Time frame: Baseline to 26 weeks

Secondary outcomes

  1. Change in kidney cortical relaxation rates (R2*)

    Measurement of oxygenation by magnetic resonace imaging

    Time frame: Baseline to 26 weeks

  2. Change in estimated glomerular filtration rate

    Estimated glomerular filtration rate will be calculated from age, sex, and the serum concentrations of creatinine and cystatin C

    Time frame: Baseline to 26 weeks

  3. Change in glucose time in range

    Proportion of time with glucose 70-180 mg/dL measured by continuous glucose monitoring

    Time frame: Baseline to 26 weeks

  4. Change in glucose coefficient of variation

    Measured by continuous glucose monitoring

    Time frame: Baseline to 26 weeks

  5. Change in total daily insulin dose

    Mean total dose of insulin administered per day

    Time frame: Baseline to 26 weeks

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Kugathasan L, Aronson Y, Sridhar VS, Ni H, Ouimet JP, Limonte CP, Sarma S, Cherney DZI. Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease. Expert Rev Clin Immunol. 2025 Aug;21(8):1113-1134. doi: 10.1080/1744666X.2025.2537446. Epub 2025 Jul 24. PubMed 40693871 ↗

Individual participant data

Plan to share: Yes — The study team will field direct requests from other researchers to share deidentified data after completion of the trial.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jun 2027, 38 months after the start.

Of 52 phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2023
First posted
Apr 21, 2023
StartActual
Apr 5, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05822609
Collaborators
Juvenile Diabetes Research Foundation, University of Colorado, Denver, Providence Healthcare, University of Toronto
Responsible party
Ian deBoer (Professor, School of Medicine, University of Washington) — Principal investigator
First posted
Apr 21, 2023
Start date
Apr 5, 2024
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 2, 2026

Study contacts

Ernest Ayers, MSPH
Contact
ayerse@uw.edu
206-685-1423
Leila Zelnick, PhD
Contact
lzelnicke@uw.edu
206-543-2981
Ian de Boer, MD, MS
principal investigator · University of Washington
Jessica Kendrick, MD
principal investigator · University of Colorado Anschutz Medical Campus and Children's Hospital Colorado
David Cherney, PhD, MD
principal investigator · University of Toronto
Irl Hirsch, MD
principal investigator · University of Washington
Katherine Tuttle, MD
principal investigator · Providence Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion